The Discounted Cash Flow (DCF) valuation of Intra-Cellular Therapies Inc (ITCI) is (516.50) USD. With the latest stock price at 131.87 USD, the upside of Intra-Cellular Therapies Inc based on DCF is -491.7%.
Based on the latest price of 131.87 USD and our DCF valuation, Intra-Cellular Therapies Inc (ITCI) is a sell. selling ITCI stocks now will result in a potential gain of 491.7%.
Note: valuation result may not be accurate due to the company's negative earnings.
| Range | Selected | |
| WACC / Discount Rate | 5.3% - 7.0% | 6.2% |
| Long-term Growth Rate | 3.0% - 5.0% | 4.0% |
| Fair Price | (3,664.62) - (279.67) | (516.50) |
| Upside | -2879.0% - -312.1% | -491.7% |